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BACKGROUND: Rat trachea display a differential topo-
graphical distribution of connective tissue mast cells
(CTMC) and mucosal mast cells (MMC) that may
imply regional differences in the release of allergic
mediators such as tumor necrosis factor-a (TNF-a)
and eicosanoids.
Aim: To evaluate the role of CTMC and MMC for
release of TNF-a and eicosanoids after allergenic
challenge in distinct segments of rat trachea.
Materials and methods: Proximal trachea (PT) and
distal trachea (DT) from ovalbumin (OVA)-sensitized
rats, treated or not with compound 48/80 (48/80) or
dexamethasone, were incubated in culture medium.
After OVA challenge, aliquots were collected to study
release of TNF-a and eicosanoids.
Results: Release of TNF-a by PT upon OVA challenge
peaked at 90 min and decayed at 6 and 24 h. Release
from DT peaked at 30 
/90 min and decayed 6 and 24 h
later. When CTMC were depleted with 48/80, OVA
challenge exacerbated the TNF-a release by PT at all
time intervals, while DT exacerbated TNF-a levels 6
and 24 h later only. Dexamethasone reduced TNF-a
production after 90 min of OVA challenge in PT and at
3 and 6h in DT. OVA challenge increased prostaglan-
din D2 in DT and leukotriene B4 in both segments but
did not modify prostaglandin E2 and leukotriene C4
release.
Conclusion: OVA challenge induces TNF-a release
from MMC, which is negatively regulated by CTMC.
The profile of TNF-a and eicosanoids depends on the
time after OVA challenge and of the tracheal segment
considered.
Key words: TNF, Eicosanoids, Mast cells, Airways, Asth-
ma, Rat
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Introduction
Asthma is an inflammatory airways disease character-
ized by migration of inflammatory cells to the air-
ways, bronchoconstriction and bronchial hyper-
responsiveness (BHR).
1 During its initial phases,
activated mast cells release a wide spectrum of
preformed and newly generated mediators including
histamine and 5-hydroxytryptamine, tumor necrosis
factor-a (TNF-a), arachidonic acid (AA) metabolites,
proteases and nitric oxide.
2 The release of those
mediators induces different pathophysiologic effects,
including bronchoconstriction and excessive mucus
production and secretion associated with respiratory
disorders.
3 In addition, these mediators have an
important role in regulating the subsequent chain of
pulmonary inflammatory events.
4
One of the major mast cell-derived cytokines is
TNF-a and its effects on airway inflammation are well
recognized.
5 Generation of TNF-a was also demon-
strated in the bronchoalveolar lavage fluid from
antigen-challenged animals and from asthmatic pa-
tients.
6 8 TNF-a receptor antagonists have been
shown to prevent BHR in a model of allergic
inflammation.
9 TNF receptors have been identified
in human airway smooth muscle
10 and, accordingly,
TNF-a might play a role in regulating the intrinsic
properties of airway smooth muscles. This may
account for the fact that isolated trachea incubated
with TNF-a are more responsive to cholinergic
stimuli.
11,12 Preformed immunoreactive TNF-a has
been observed within the granules of mast cells,
indicating the likelihood of its rapid release after mast
cell activation.
13 16 AA metabolites such as prosta-
glandins (PGs) and leukotrienes (LTs) are also
vigorously released after mast cell activation.
17 PGs
display a number of stimulatory and/or inhibitory
effects on airway smooth muscle. For instance, PGD2
induces eosinophil recruitment, bronchoconstriction
and BHR.
18 On the contrary, PGE2, which is also
released by airway epithelial and smooth muscle
cells, acts as a protective relaxing prostanoid,
19 20 as
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237does PGE1 under conditions where PGI2 is inactive
and only suppresses aggregation of circulating plate-
lets.
21 Furthermore, PGE2 exerts potent effect on
airway epithelial wound closure,
22 suggesting a
protective role on epithelial damage such as ob-
served in asthma.
Leukotrienes are also important participants in the
allergic response of the airways.
23 Once released,
they induce mucus secretion, and increase vascular
permeability, leukocyte recruitment and potent air-
way smooth muscle contraction.
24 Antigen challenge
induces airway epithelial and smooth muscle cell
hypertrophy, which is presumably mediated by LTC4
and LTD4.
25 27
Two distinct mast cell phenotypes are well char-
acterized: connective tissue mast cells (CTMC) and
mucosal mast cells (MMC).
28 These variants differ in
many aspects, including in their responses to drugs
and secretagogues.
2,29,30 Thus, CTMC are sensitive to
depletion by compound 48/80,
31 whereas dexa-
methasone prevents MMC activation. Cytoplasmic
granules of CTMC are rich in heparin and histamine,
whereas in MMC the cytoplasmic granules contain
the proteoglycan chondroitin-6-suphate but low
concentrations of histamine.
2 Another difference
between MMC and CTMC is the pattern of AA-derived
metabolites. The predominant AA metabolite of
CTMC is PD2, whereas MMC generate predominantly
lipoxygenase products such as LTD4 and LTE4.
32,33
A differential distribution of CTMC and MMC on rat
trachea has been described.
34 Isolated distal tracheal
segments are hyper-responsiveness to antigen chal-
lenge as compared with proximal tracheal seg-
ments,
35 a fact that was attributed to differences in
mast cell distribution.
34 Therefore, it is plausible that
anatomical organization of airways leads to physio-
logically relevant regional differences related to the
heterogeneity of mast cells. Since airways are rich in
CTMC and MMC, we decided to investigate the
potential influence of the mast cell heterogeneity in
rat trachea on the release of TNF-a and of eicosa-
noids, after in vitro antigen challenge of proximal
and distal tracheal segments.
Materials and methods
Animals
Male Wistar rats (180 /220 g) from our departmental
animal facilities were housed in plastic cages (18.5
cm /18.5 cm /13.5 cm), five rats per cage, in a
light/temperature-controlled room (12 h/12 h, 219 /
28C). All experiments received prior approval from
the Animal Care Committee from the Institute of
Biomedical Sciences of the University of Sa ˜o Paulo.
Sensitization
The rats were sensitized by an intraperitoneal injec-
tion of 10 mg of ovalbumin (OVA) mixed with 10 mg
of aluminum hydroxide (day 0). One week later (day
7), the rats were boosted with 10 mg of OVA dissolved
in saline by a subcutaneous injection. The OVA
challenge was carried out in isolated segments from
proximal and distal trachea 14 days later.
Isolation and incubation of tracheal segments
After 14 days of sensitization, the rats were killed
under deep chloral hydrate anesthesia ( /400 mg/
kg, intraperitoneally), exsanguinated by cutting the
neck vessels and the thoracic cavity, then opened.
The trachea was removed and dissected free of
connective tissue before being divided into two
portions of similar weight (21.39 /2.0 mg). Tracheal
rings were designated as proximal (corresponding to
the first three to five cartilaginous rings closest to the
larynge) or distal (corresponding to the last three to
five cartilaginous rings closest to the carine) seg-
ments.
35 The segments of trachea were put into 24-
well plastic microplates containing 1 ml of RPMI 1640
medium enriched with 10% fetal calf serum and
maintained under 5% CO2 atmosphere at 378C.
Antigen challenge
After 60 min of equilibrium, the antigen challenge
was performed by OVA addition (final concentration,
100 mg/ml) into the tracheal cultures. Aliquots of the
supernatant (100 ml) were collected after 30 and 90
min as well as after 3, 6 and 24 h, and stored at  /208C
until further use.
Determination of TNF activity
The levels of TNF were measured in aliquots from
supernatant of tracheal culture using the L-929
cytotoxicity assay.
36 In brief, properly diluted sam-
ples (100 ml) were added to the 96-well microplates
containing target L-929 cells (5 /10
4 cells/100 ml) in
the presence of actinomycin D (final concentration, 5
mg/ml) and incubated during 20 h at 378C. The
supernatants were discarded and the remaining
viable adherent cells were stained with crystal violet
(0.05%) during 15 min. The absorbance was read at
620 nm (ELISA Titertek Multiskan, Lab Systems,
Helsinki, Finland). The TNF titer (U/ml) was defined
as the reciprocal of the dilution, which induced 50%
of L-929 cell lysis.
Eicosanoid release
In this series of experiments we quantified the release
of eicosanoids in selected times after OVA challenge.
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37
the concentrations of PGE2, PGD2, LTB4 and LTC4
were determined 30 and 90 min after OVA challenge.
In brief, during 18 h, properly diluted samples of
supernatant (100 ml) from tracheal cultures were
incubated with acetylcholinesterase-conjugated eico-
sanoid plus the specific antiserum, in 96-well micro-
titer plates coated with anti-immunoglobulin G
immunoglobulin. Two hours after acetylcholine ad-
dition, the optical density was determined at 412 nm
in a microplate reader and the concentration of
eicosanoids calculated using standard curves.
Effects of pharmacological treatments on OVA-
induced TNF production
Compound 48/80. After 10 days of OVA sensitiza-
tion, groups of rats received 100 mg of compound 48/
80 in the morning and evening of the first day,
increasing in 100 mg increments to 500 mg in the
morning and evening of the fifth day. According to
the literature, such a protocol of administration of
compound 48/80 depletes up to 90% of CTMC rat
trachea.
34
Dexamethasone. Groups of sensitized rats were
treated by intraperitoneal injection of dexamethasone
(1 mg/kg) 18 h before killing the animals. The OVA
challenge and the quantification of the levels of TNF
were performed as already indicated.
Fixation processing and embedding for light
microscopy
After 24 h of in vitro treatment, fragments of trachea
were fixed in 4% paraformaldehyde and 0.5% glutar-
aldehyde, 0.1 M of sodium cacodylate buffer (pH 7.4)
for 2 h at 48C, washed in sodium cacodylate,
dehydrated through a grade series of ethanol, and
embedded in UNICRIL
th resin (British BioCell Inter-
national, Cardiff, UK) for light microscopy analysis
and for immunohistochemistry. Sections (1.5 mm
thick) were cut on an ultramicrotome (Reichert
ULTRACUT UCT-GA, Leica, Wien, Austria) and
stained with toluidine blue 1% in 0.1 M of sodium
cacodylate buffer.
Immunohistochemistry
To analyze the proteoglycan heparin in the CTMC
and MMC, and confirm the presence of this in the
former mast cell type, UNICRYL sections (1 mm thick)
were prepared in histological slides and incubated
with the followed reagents: washed in 0.1 M of Tris
buffer (Sigma Chemical Co., Poole, UK) (pH 8.2) for
30 min with 3% hydrogen peroxide, then washed
again three times in Tris buffer for a further 30 min.
Non-specific binding sites were blocked with 10%
chicken egg albumin in Tris buffer (TBAE). The
degree of mast cell differentiation was analyzed
with the serum monoclonal antibody anti-heparin
(ST-1).
38 The sections were incubated overnight at
48C. As a control of the reaction, sections were
incubated with non-immune IgM mouse serum
(Sigma Chemical Co.) instead of the primary anti-
body. Sections were washed in 1% TBAE for 40 min
before incubation for 1 h at room temperature with
the secondary antibody, an anti-mouse IgM (Fc
fragment specific) antibody conjugated to 5 nm
colloidal gold (1:100; British BioCell International,
Cardiff, UK). Sections were washed in Tris buffer (30
min) and washed in distilled water (30 min). Silver
enhancing solution SEKL (British BioCell Interna-
tional) was used to augment gold particle staining.
39
At the end of the reaction, sections were washed
thoroughly in distilled water, counterstained with
hematoxylin and eosin and mounted in BIOMOUNT
(British BioCell International). Finally, serial sections
of trachea were stained with 1% toluidine blue in 1%
sodium borate solution, and the same field being re-
photographed on the ZEISS-AXIOSKOP2 (Zeiss, Mot,
Go ¨ttingen, Germany) microscope.
Data handling and mast cell quantification
For quantification of the histological preparations,
first an observer unaware of the treatment counted
the number of mast cells in each tracheal section, and
the percentage of degranulated mast cells was sub-
sequently quantified. Data were determinate using a
high-power objective (x 40), and the number of mast
cells was counted in tree areas of approximately 100
mm
2 using three serial sections (1.5 mm each, leaving
20 mm space between each section) from each
tracheal segment (n /5 per group). In all cases,
data are expressed as mean9 /standard error of the
mean.
Results
Analysis of tracheal mast cell heterogeneity and
of the effects of OVA challenge
The presence of metachromatic granules in rat
tracheal mast cells was determined by light micro-
scopy after toluidine blue staining. Initially, the
distinction between CTMC and MMC was based on
their anatomical distribution. The CTMC were found
in smooth muscle and adventitia (Fig. 1A), whereas
MMC were localized mainly in the mucosal layer,
near the epithelium (Fig. 1A). CTMC could be also
identified by their size and intense metachromatic
cytoplasmatic granules that were highlighted for
immunostaining with the anti-heparin monoclonal
TNF and lipid mediators in allergic airway reaction
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eactive to this antibody (Fig. 1B).
After OVA challenge, a high number of degranu-
lated CTMC (proximal trachea, 90%; distal trachea,
91%) and MMC (proximal trachea, 91%; distal
trachea, 77%) (Tables 1 and 2) were observed in
sections. Mast cell degranulation was identified by
the presence of metachomatic granules in the extra-
cellular matrix around the cell.
Proximal and distal tracheal segments
differentially release TNF-a after OVA challenge
Fig. 2 shows the time-dependent TNF-a activity
found in supernatants from segments of proximal
and distal trachea collected from sensitized rats and
challenged in vitro with OVA. Both proximal and
distal segments (hatched and solid bars, respectively)
provided a bell-shaped curve for TNF-a activity.
Thirty minutes after challenge, the levels of TNF-a
FIG. 1. Morphology of MMC and CTMC in rat trachea tissue sections. (A) Tracheal MMC in the basal group showed
metachromatic cytoplasmatic granules in the mucosal layer (arrow), whereas the CTMC subtype was predominantly localized
in smooth muscle and adventitious layers (arrowheads). Toluidine blue stain. (B) Presence of ST-1 (anti-heparin monoclonal
antibody) immunoreactivity in CTMC (arrowheads) and absence of staining in MMC (arrow). Hematoxylin and eosin stain. Bar,
10 mm.
Table 1. Cumulative data for mast cell numbers in rat proximal trachea
CTMC MMC
Intact Degranulated % Degranulated Intact Degranulated % Degranulated
Saline 4.259 /0.06 0 0 6.79 /0.8 0 0
C48/48 n.d. n.d. n.d. 6.99 /0.2 0 0
OVA 0.49 /0.2* 3.49 /0.5* 90 0.69 /0.4* 5.89 /0.6* 91
C48/48  /OVA n.d. n.d. n.d. 0.99 /0.2** 5.49 /0.5** 86
DEXA  /OVA 2.89 /0.2** 1.79 /0.5** 38 3.99 /0.5** 3.19 /0.2** 44
Extent of intact and degranulated CTMC and MMC (as measured in 100 mm
2 of 1.5 mm sections) after 24 h in vitro OVA challenge. Compound 48/
80 (C48/80) and dexamethasone (DEXA) treatments were performed as indicated in Materials and methods. The presence of intact and
degranulated mast cells and the relative percentages are shown. Data represent mean9 /standard error of the mean of n /5 rats per group.
*pB/0.05 versus saline group; **pB/0.05 versus OVA group; n.d.: not detected.
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were low (1.59 /0.3 U/ml), and reached a peak 90
min (21.39 /3.4 U/ml) and 3 h later (27.49 /1.5 U/ml).
TNF-a titers fell down subsequently, remaining still
approximately 10-fold above the basal levels (0.59 /
0.01 U/ml) at 24 h (4.89 /0.2 U/ml).
TNF-a activity quantified in distal segments (30.79 /
7.4 U/ml) 30 min after OVA challenge was approxi-
mately 20-fold above the amounts produced by the
proximal segments, and 60 times above the respec-
tive basal values (0.59 /0.01 U/ml). At 3 h, the levels
of TNF-a (40.49 /3.4 U/ml) were similar to those
found at 90 min. Six hours later, the titers of TNF were
reduced (179 /1.4 U/ml) but after 24 h these levels
were 4.59 /0.4 U/ml (i.e. above the basal values).
Effects of compound 48/80 on the OVA-induced
TNF-a release
Groups of sensitized rats were treated with com-
pound 48/80 using a well-recognized protocol (see
Materials and methods) that depleted the CTMC
population from both distal and proximal trachea
(Tables 1 and 2). OVA challenge induced mast cell
degranulation in the proximal and in the distal
tracheal segments. Intact CTMC after in vivo treat-
ment with compound 48/80 was not detected in both
segments, but the number of intact MMC was not
modified. The extent of MMC degranulation induced
by OVA challenge was similar in both groups, treated
or not with compound 48/80 (Tables 1 and 2). As
observed in Fig. 3A, the proximal tracheal segments
from rats pretreated with compound 48/80 released
significantly higher amounts of TNF-a 90 min after
OVA challenge than matched immunized and chal-
lenged rats unexposed to compound 48/80 (treated,
71.39 /16.2 U/ml; non-treated, 21.49 /2.8 U/ml).
Those elevated levels of TNF-a were also found 3,
6 and 24 h after OVA challenge.
The TNF-a activity released by distal tracheal
segments from rats pretreated by compound 48/80
Table 2. Cumulative data for mast cell numbers in rat distal trachea
CTMC MMC
Intact Degranulated % Degranulated Intact Degranulated % Degranulated
Saline 8.79 /0.5 0 0 1.09 /0.2 0 0
C48/48 n.d. n.d. n.d. 0.99 /0.2 0 0
OVA 0.89 /0.3* 8.39 /0.3* 91 0.39 /0.2* 1.09 /0.4* 77
C48/48  /OVA n.d. n.d. 0 0.29 /0.2 0.79 /0.2 78
DEXA  /OVA 6.39 /0.4** 2.39 /0.2** 27 0.69 /0.2** 0.49 /0.1** 40
Extent of intact and degranulated CTMC and MMC (as measured in 100 mm
2 of 1.5 mm sections) after 24 h in vitro OVA challenge. Compound 48/
80 (C48/80) and dexamethasone (DEXA) treatments were performed as indicated in Materials and methods. The presence of intact and
degranulated mast cells and the relative percentages are shown. Data represent mean9 /standard error of the mean of n /5 rats per group.
*pB/0.05 versus saline group; **pB/0.05 versus OVA group; n.d.: not detected.
FIG. 2. Temporal proﬁle of TNF-a activity in supernatants
from proximal and distal tracheal segments after OVA
challenge. Segments obtained from 14-day sensitized rats
were isolated and placed in 24-well plates containing RMPI
1640 culture medium. OVA challenge was performed after 60
min, allowing for equilibrium. After the indicated time
intervals, samples (100 ml) were recovered for TNF-a deter-
mination by the L-929 bioassay. The data represent mean9 /
standard error of the mean from nine to 13 experiments. a,
pB/0.05 in comparison with basal levels; b, pB/0.05 in
comparison with the proximal segments.
FIG. 3. Effect of in vivo treatment with compound 48/80 on
the TNF-a activity in supernatants from proximal (A) and
distal (B) tracheal segments after OVA challenge. Procedures
as in Fig. 2. The control group consisted of rats treated with
phosphate-buffered saline. The data represent mean9 /stan-
dard error of the mean from four to 11 experiments. a, pB/
0.05 in comparison with the respective control segment.
TNF and lipid mediators in allergic airway reaction
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after OVA challenge was significantly increased as
compared with the untreated group (6 h, 17.79 /1.4
U/ml; 24 h, 4.59 /0.4 U/ml), contrasting to the levels
of TNF-a at 90 min and 3 h after OVA challenge that
were not affected by pretreatment with compound
48/80.
Inhibition by dexamethasone of OVA-induced
TNF-a release
Fig. 4 shows the effects of dexamethasone treatment
of sensitized rats on TNF-a released after in vitro
OVA challenge of proximal (upper panel) and distal
(low panel) tracheal segments. As noted, reduced
amounts of TNF-a were released by the proximal
tracheal segments 90 min after OVA challenge (1.89 /
0.3 U/ml), whereas increased levels were produced
by tracheal segments from the untreated group
(23.69 /3.7 U/ml). In addition, increased and similar
levels of TNF-a were found in both, control and
treated groups, 3, 6 and 24 h after OVA challenge.
Dexamethasone significantly reduced the TNF-a
activity produced by the distal segments (lower
panel) 3 h (2.29 /0.7 U/ml) and 6 h (1.59 /0.3 U/ml)
after OVA challenge, as compared with the respective
control group. Dexamethasone also reduced the
number of degranulated CTMC and MMC in proximal
tracheal segments (38% and 44%) (Table 1) and distal
tracheal segments (27% and 40%) (Table 2) as
compared with the untreated group
Effects of antigen challenge on eicosanoid
production
Fig. 5 summarizes the results when eicosanoids were
determined 30 min and 90 min after in vitro OVA
challenge of tracheal segments isolated from sensi-
tized rats. Fig. 5A shows that even though the basal
production of PGE2 by proximal (4.09 /0.4) and distal
(1.89 /0.5) segments was significantly different, these
values were not affected 30 or 90 min after OVA
challenge. PGD2 production by distal tracheal seg-
ments was significantly increased 30 min (4.09 /0.8)
and 90 min (4.49 /0.8) after OVA challenge, as
compared with control (unchallenged) segments
(0.79 /0.1), whereas its production by proximal tra-
cheal segments after OVA challenge was not different
from those obtained in the unchallenged group
(16.29 /5.6). Fig. 5C shows the significant increases
of the production of LTB4 by proximal and distal
tracheal segments 30 min (proximal, 0.0779 /0.006;
distal, 0.29 /0.06) and 90 min (proximal, 0.239 /0.02;
distal, 0.39 /0.007) after OVA challenge, as compared
with the values obtained from the control unchal-
lenged group (proximal, 0.0429 /0.005; distal, 0.0419 /
0.001). Fig. 5D indicates that LTC4 production was
not affected, at any studied time point, after OVA
challenge when compared with the control group.
Discussion
In this study we quantified the production of TNF-a
and of eicosanoids in supernatants from proximal
and distal tracheal segments of rats at distinct time
intervals after in vitro OVA challenge, and studied the
interference of dexamethasone, an effective suppres-
sor of TNF-a production. Moreover, to study the
influence of the heterogeneity of mast cell mediators
on TNF-a production, we pretreated the rats with the
selective CTMC-degranulating agent compound 48/
80
31 before challenging the isolated trachea with
OVA.
Distal tracheal segments released rapidly signifi-
cant amounts of TNF-a after challenge. This release
peaked at 30 min and decayed after 6 and 24 h. By
contrast, maximal values of TNF-a were released by
proximal tracheal segments 90 min after OVA chal-
lenge, showing a significant difference between the
tracheal segments with respect to the ability to
release TNF-a. Our evidence, in conjunction with
the reported release of high amounts of TNF-a after
antigen challenge,
6 8 suggests that tracheal mast cells
are the major source of TNF-a produced after
FIG. 4. Effect of in vivo treatment with dexamethasone (1 mg/
kg intraperitoneally) on the TNF-a activity in supernatants
from proximal (upper panel) and distal (lower panel) tracheal
segments submitted to OVA challenge. Procedures as in Fig.
2. Data represent mean9 /standard error of the mean from
ﬁve to 10 experiments. a, pB/0.05 in comparison with the
respective control segment.
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dependent TNF-a activity in supernatants from tra-
cheal segments correlated positively with mast cells
degranulation caused by OVA (Tables 1 and 2).
The study of the effects of in vitro OVA challenge
on tracheal segments is a useful addition to the
standard investigations concerning the contraction of
reactivity of smooth muscle caused by allergen.
40,41
Similar procedures have been applied to study the
effects of cytokines in lung fragments, as well as in
isolated airways and airway smooth muscle cells in
culture.
42 45 In fact, using the distinct tracheal seg-
ments, we could analyze the effects of OVA challenge
on the mast cell subtypes and their role in modulating
TNF-a release.
CTMC and MMC display distinct functional activ-
ities, resulting at least in part from a different profile
of the inflammatory mediators release by these cells.
Mast cells, when properly activated, release rapidly
preformed stores of TNF-a, followed by its synthesis
and sustained release.
46 48 Since TNF-a participates
in allergic airway hyperreactivity,
9,45 we decided to
investigate whether the differential pattern of TNF-a
release from the proximal and distal tracheal seg-
ments might be explained in terms of the hetero-
geneous mast cell population. Compound 48/80 is a
selective CTMC-degranulating agent, and the dosage
regimen utilized in this study confirmed its efficacy in
depleting the tracheal CTMC without affecting the
MMC population.
34 Treatment with compound 48/80
modified profoundly the temporal profile of the
release of TNF-a by both tracheal segments (see
Fig. 3). Interestingly, in proximal tracheal segments,
the depletion of CTMC exacerbated the release of
TNF-a at all time intervals studied, whereas in distal
tracheal segments the absence of CTMC affected the
release of TNF-a caused by OVA challenge only after
6 h and 24 h. Since we postulated an influence of
mast cell heterogeneity on the profile of the temporal
release of TNF-a, we investigated the distribution of
mast cells in both tracheal segments. First, we
observed that OVA challenge was effective in degra-
nulating mast cells in both segments of trachea
(around 90%). Subsequently, we characterized a
different pattern of distribution of MMC in tracheal
segments, as compared with CTMC. The number of
CTMC and of MMC in the proximal segments was
similar, but in the distal segments CTMC were more
numerous (Tables 1 and 2). Therefore, it is possible
that the differential release of TNF-a caused by OVA
challenge by proximal and by distal tracheal segment
is accounted for by the presence of different popula-
tions of mast cells in these segments. Proximal and
distal isolated tracheal segments show different
degrees of responsiveness to allergic challenge, to
serotonin, histamine, acetylcholine and to nitric
oxide.
35,49 51 Morphological analyses of both tra-
cheas after in vivo treatment with compound 48/80
revealed that MMC constitute the only source of mast
cells available for subsequent response to OVA. Since
we observed a significant shift in release of TNF-a
after OVA challenge in proximal and distal trachea, a
FIG. 5. Eicosanoid levels in supernatant from proximal (hatched bars) and distal (solid bars) tracheal segments after OVA
challenge. Tracheal segments were isolated and placed in 24-well plates containing RMPI 1640 culture medium. After the
indicated time intervals, samples (100 ml) were recovered and PGE2 (A), PGD2 (B), LTB4 (C) AND LTC4 (D) were measured by
enzyme immunoassay. Control groups consisted of tracheal segments from non-challenged tissues. Data represent mean9 /
standard error of the mean from ﬁve separate experiments. Symbols over bars indicate signiﬁcant differences: a, pB/0.05 in
relation to the respective control; b, pB/0.05 in relation to the proximal segment.
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the release of TNF-a after OVA challenge can by
hypothesized (see Tables 1 and 2 and Fig. 3). In
addition, our data suggest that TNF-a originates from
MMC. In fact, MMC are the major mast cell subtype
involved in increased vascular permeability induced
by OVA challenge in rats.
52
Globally, our results allow one to hypothesize the
existence of a system of regulation of the generation
of TNF-a by MMC, controlled negatively by CTMC
from both pools, stocked and newly formed TNF-a.
Although our data do not permit one to identify the
exact source of TNF-a, it is probable that proximal
and distal rat tracheal cells play different roles in the
regulatory mechanisms of the production of TNF-a
by airway undergoing allergic response. In this
context, we suggest that, after OVA challenge,
CTMC and MMC are called into play distinctly, which
results in a differential pattern of control of TNF-a
release, where CTMC activates negatively the TNF-a
release by MMC.
It is conceivable that CTMC modulates TNF-a
production through the production of annexin-1,
53
modulating acute and even the late allergic response.
In addition, TNF-a is also released by macrophages,
whose functional activities are modulated by PGE2,
54
which is released by CTMC upon challenge. This
mechanism may represent a counterbalance against
the inflammatory effects caused by the allergenic
challenge. In addition, a local feedback loop may
operate, since there is evidence that TNF-a can also
decrease mast cell activation.
55 Dexamethasone re-
duces the mast cells degranulation caused following
OVA aerolization.
52 Since inhibition by dexametha-
sone of the production and release of cytokines,
including TNF-a, is well documented,
56,57 we treated
rats with dexamethasone and analyzed the release of
TNF-a after OVA challenge. In the proximal tracheal
segments, dexamethasone partially reduced mast
degranulation and prevented the release of TNF-a
90 min after OVA challenge. Glucocorticoids inhibit
TNF-a gene expression mainly through post-tran-
scriptional mechanisms.
56 Thus, our data are indica-
tive that the TNF-a quantified at 90 min after OVA
challenge is newly synthesized by mast cells, whereas
at 3, 6 and 24 h TNF-a must originate from stored
pools. These data agree with the view that mast cell
activation via FcgRI accounts for rapid release of
TNF-a.
2 Interestingly, the lack of effect of dexametha-
sone on the release of TNF-a in distal trachea 90 min
after OVA challenge provides additional support to
our view that the early TNF-a activity produced by
distal segments results from the release of stocked
TNF-a. By contrast, TNF-a release at 3 and 6 h might
depend on its synthesis. The overall picture is that
MMC and CTMC, which are equally present in the
proximal segments, constitute the main sources of
early (90 min) newly synthesized TNF-a, which is
sensitive to inhibition by dexamethasone. On the
contrary, TNF-a released later (at 3, 6 and 24 h)
should come from stocked pools and therefore is
refractory to inhibition by dexamethasone. CTMC are
abundant in distal segments, and may be the source
for the release (90 min) of stocked TNF (also resistant
to dexamethasone), whereas TNF-a released at 3 and
6 h should be newly synthesized TNF-a and therefore
dexamethasone sensitive.
A complex spectrum of release of eicosanoids by
proximal and distal tracheal segments was also
found, whether exposed or not to antigen (Fig. 5).
Neither segments released additional amounts of
PGE2 after OVA challenge. However, proximal tra-
cheal segments spontaneously released more PGE2
than distal segments. PGE2 may also interfere indir-
ectly by inhibiting mediator release from the mast
cells.
58,59 Thus, the elevated amounts of PGE2 pro-
duced may constitute an important protective me-
chanism for the airways. By contrast, the proximal
tracheal segments did not produce PGD2 after
challenge, whereas the distal tracheal segments
produced increased amounts. Distal segments show
higher amounts of CTMC (Table 2), an important cell
source of prostanoids.
32,33 In addition to its proin-
flammatory effects, PGD2 induces BHR.
18 Our data
suggest that PGE2 in proximal segments is constitu-
tively released, whereas PGD2 is released upon mast
cell activation.
Both tracheal segments produced large amounts of
LTB4 upon OVA challenge (Fig. 5). LTB4 is a major
chemotactic agent, which contributes to the exacer-
bation of airway inflammation observed in late
asthmatic response, which also stimulates vascular
permeability and smooth muscle contractions.
60,61 Its
production was quantified much more intensively in
the supernatants from the OVA-challenged proximal
as compared with the distal tracheal segments. MMC
are present in the proximal trachea and released
consistently more leukotrienes than activated CTMC,
which typically produce prostanoids,
33,34 and were
found in comparatively higher numbers in the distal
segments. Contrasting to the distal segments, where
prostanoids were found as the major eicosanoids
released, the proximal tracheal segments released
more LTB4. Despite the role of cysteinyl leukotrienes
on bronchial asthma,
62 the levels of LTC4 did not
change after antigenic challenge of the trachea. The
reason for such an apparent discrepancy is unclear.
In conclusion, we showed that, following OVA
challenge, tracheal mast cells are activated and
release TNF-a and eicosanoids. Their profile depends
on the time elapsed after antigen challenge and on
the tracheal segment considered. A differential fine
regulation of upper airways allergic responses can
thus be anticipated.
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